Drugs / measles, mumps and rubella combined vaccine, live
measles, mumps and rubella combined vaccine, live
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT04364399 Comparator | Nov 2020 | mumps infectious disease | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | measles, mumps and rubella combined vaccine, live | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04364399 ↗ |
| Modality | Vaccine | “One dose of measles, mumps and rubella combined vaccine, live: 0.5 ml per dose, mumps live virus not less than 4.3 lg CCID50” NCT04364399 ↗ |